Replies to post #27226 on NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

The Q&A portion is part of the Oppenheimer Sticky, but here's the exact portion:

Conference attendee #5: And another question that I had, is that given the timeframe that you sketched for the DCVax-L, it looks like you probably will have data in, let's say in mid-2016? What are you thinking the.

Linda Powers interrupts: No, no, no, no. No, well, if you know if the patients, umm, depending on the patients, of course. No, we think it is more like close to the turn of the year. Like the beginning of 2016, not the middle.

Conference attendee #5: Okay, okay.

Conference attendee #1: that's because the patients are doing well.

Linda Powers: But it's a prediction. Right? Any of these things are not set in stone, whatsoever, and everybody needs to kind of remember that.

[Pyrrhonian]

Completed enrollment and trial completion are of course very different things. Enrollment on track to complete late 2015. They expect to hit 248 PFS events some 6 months thereafter. That would mark trial completion. This will almost certainly not happen however, even if the trial goes on to its conclusion (of 248 events). They are basing their projection on initial trial design assumptions of 13.5 months median PFS for tx group and 7 months for control.